Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 47 articles: HTML format

Single Articles

October 2025
1. DIMOU A, Mansfield A
   EGFR-Mutated Lung Cancer - Letting the Butterfly Out of the Cocoon.
   N Engl J Med. 2025;393:1743-1745.
   PubMed    
   
   
   
2. YANG JC, Lu S, Hayashi H, Felip E, et al
   Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
   N Engl J Med. 2025;393:1681-1693.
   PubMed     Abstract available
   
   
   
3. LE X, Kim TM, Loong HH, Prelaj A, et al
   Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.
   N Engl J Med. 2025 Oct 17. doi: 10.1056/NEJMoa2511065.
   PubMed     Abstract available
   
   
   
4. RUDIN CM, Mountzios G
   Tarlatamab in Small-Cell Lung Cancer. Reply.
   N Engl J Med. 2025;393:1348-1349.
   PubMed    
   
   
   
5. YILDIZ O, Araz M
   Tarlatamab in Small-Cell Lung Cancer.
   N Engl J Med. 2025;393:1348.
   PubMed    
   
   
   August 2025
6. CALVO V
   Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy.
   N Engl J Med. 2025;393:809-810.
   PubMed    
   
   
   June 2025
7. LENTZ RJ, Frederick-Dyer K, Planz VB, Koyama T, et al
   Navigational Bronchoscopy or Transthoracic Needle Biopsy for Lung Nodules.
   N Engl J Med. 2025;392:2100-2112.
   PubMed     Abstract available
   
   
   
8. MOUNTZIOS G, Sun L, Cho BC, Demirci U, et al
   Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy.
   N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502099.
   PubMed     Abstract available
   
   
   
9. FORDE PM, Spicer JD, Provencio M, Mitsudomi T, et al
   Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer.
   N Engl J Med. 2025 Jun 2. doi: 10.1056/NEJMoa2502931.
   PubMed     Abstract available
   
   
   April 2025
10. HEYMACH JV, Ruiter G, Ahn MJ, Girard N, et al
    Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
    N Engl J Med. 2025 Apr 28. doi: 10.1056/NEJMoa2503704.
    PubMed     Abstract available
    
    
    
11. PICH O, Bernard E, Zagorulya M, Rowan A, et al
    Tumor-Infiltrating Clonal Hematopoiesis.
    N Engl J Med. 2025;392:1594-1608.
    PubMed     Abstract available
    
    
    December 2024
12. SENAN S
    Durvalumab in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;391:2386.
    PubMed    
    
    
    
13. PETRELLI F, Dottorini L, Ghidini A
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385-2386.
    PubMed    
    
    
    
14. RAMELLA S, Ippolito E, D'Angelillo RM
    Durvalumab in Small-Cell Lung Cancer.
    N Engl J Med. 2024;391:2385.
    PubMed    
    
    
    October 2024
15. CHO BC, Lu S, Felip E, Spira AI, et al
    Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2024;391:1486-1498.
    PubMed     Abstract available
    
    
    September 2024
16. CHENG Y, Spigel DR, Cho BC, Laktionov KK, et al
    Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    N Engl J Med. 2024 Sep 13. doi: 10.1056/NEJMoa2404873.
    PubMed     Abstract available
    
    
    
17. WITTROCK E, Hagner MD
    Cannonball Pulmonary Lesions.
    N Engl J Med. 2024;391:844.
    PubMed    
    
    
    August 2024
18. LEIGHL NB
    Osimertinib in Stage III EGFR-Mutated NSCLC - Game, Set, Match.
    N Engl J Med. 2024;391:652-654.
    PubMed    
    
    
    
19. LU S, Kato T, Dong X, Ahn MJ, et al
    Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC.
    N Engl J Med. 2024;391:585-597.
    PubMed     Abstract available
    
    
    
20. CASCONE T, Spicer JD, Provencio Pulla M
    Perioperative Nivolumab in Resectable Lung Cancer. Reply.
    N Engl J Med. 2024;391:573-574.
    PubMed    
    
    
    
21. SORSCHER S
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:573.
    PubMed    
    
    
    
22. SOBRERO S, Vaisitti F, Leo F
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;391:572-573.
    PubMed    
    
    
    June 2024
23. VIDULA N, Rodriguez K, Wong AK, Boyraz B, et al
    Case 17-2024: A 45-Year-Old Woman with Metastatic Breast Cancer.
    N Engl J Med. 2024;390:2011-2022.
    PubMed    
    
    
    May 2024
24. GARASSINO MC, Torri V
    Neoadjuvant or Perioperative Approach in Lung Cancer.
    N Engl J Med. 2024;390:1816-1818.
    PubMed    
    
    
    
25. CASCONE T, Awad MM, Spicer JD, He J, et al
    Perioperative Nivolumab in Resectable Lung Cancer.
    N Engl J Med. 2024;390:1756-1769.
    PubMed     Abstract available
    
    
    April 2024
26. PASSARO A, Peters S
    Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now.
    N Engl J Med. 2024;390:1325-1327.
    PubMed    
    
    
    
27. WU YL, Dziadziuszko R, Ahn JS, Barlesi F, et al
    Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:1265-1276.
    PubMed     Abstract available
    
    
    
28. IZZEDINE H, Bouderlique E, Besse B
    Selpercatinib and Pseudo-Decreases in Kidney Function.
    N Engl J Med. 2024;390:1241-1243.
    PubMed    
    
    
    February 2024
29. ZHOU C, Agrawal T, Girard N
    VTE with Amivantamab plus Chemotherapy in NSCLC. Reply.
    N Engl J Med. 2024;390:579-580.
    PubMed    
    
    
    
30. MOIK F, Riedl JM, Ay C
    VTE with Amivantamab plus Chemotherapy in NSCLC.
    N Engl J Med. 2024;390:578-579.
    PubMed    
    
    
    
31. PLANCHARD D, Janne PA, Kobayashi K
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2024;390:478-479.
    PubMed    
    
    
    
32. VAN WAALWIJK VAN DOORN-KHOSROV, Badrising SK, Burgers S
    Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
    N Engl J Med. 2024;390:478.
    PubMed    
    
    
    January 2024
33. HEYMACH JV, Harpole D, Reck M
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2024;390:287-288.
    PubMed    
    
    
    
34. HORITA N, Fujiwara Y
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:287.
    PubMed    
    
    
    
35. DRILON A, Camidge DR, Lin JJ, Kim SW, et al
    Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    N Engl J Med. 2024;390:118-131.
    PubMed     Abstract available
    
    
    November 2023
36. ZHOU C, Tang KJ, Cho BC, Liu B, et al
    Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
    N Engl J Med. 2023;389:2039-2051.
    PubMed     Abstract available
    
    
    
37. PLANCHARD D, Janne PA, Cheng Y, Yang JC, et al
    Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
    N Engl J Med. 2023;389:1935-1948.
    PubMed     Abstract available
    
    
    
38. MULLIGAN L
    Selective RET Kinase Inhibitors and Lung Cancer.
    N Engl J Med. 2023;389:1913-1916.
    PubMed    
    
    
    
39. MCCANNON JB, Shepard JO, Wong AK, Thomas MF, et al
    Case 35-2023: A 38-Year-Old Woman with Waxing and Waning Pulmonary Nodules.
    N Engl J Med. 2023;389:1902-1911.
    PubMed    
    
    
    
40. ZHOU C, Solomon B, Loong HH, Park K, et al
    First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC.
    N Engl J Med. 2023;389:1839-1850.
    PubMed     Abstract available
    
    
    
41. WU YL, Zhou Q
    Combination Therapy for EGFR-Mutated Lung Cancer.
    N Engl J Med. 2023 Nov 8. doi: 10.1056/NEJMe2311559.
    PubMed    
    
    
    October 2023
42. HEYMACH JV, Harpole D, Mitsudomi T, Taube JM, et al
    Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 23. doi: 10.1056/NEJMoa2304875.
    PubMed     Abstract available
    
    
    
43. AHN MJ, Cho BC, Felip E, Korantzis I, et al
    Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer.
    N Engl J Med. 2023 Oct 20. doi: 10.1056/NEJMoa2307980.
    PubMed     Abstract available
    
    
    
44. PROVENCIO M, Massuti B, Romero A
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2023;389:1534-1535.
    PubMed    
    
    
    
45. VERMA S, Vincent M, Breadner D
    Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2023;389:1534.
    PubMed    
    
    
    
46. TSUBOI M, Herbst RS, Wu YL
    Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
    N Engl J Med. 2023;389:1342.
    PubMed    
    
    
    
47. DI MAIO M
    Osimertinib in Resected EGFR-Mutated NSCLC.
    N Engl J Med. 2023;389:1341-1342.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.